Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Ovarian Neoplasms 18Breast Neoplasms 15Endometrial Neoplasms 11Uterine Cervical Neoplasms 5Carcinoma, Ovarian Epithelial 5Triple Negative Breast Neoplasms 4Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Prostatic Neoplasms 3Neoplasms by Site 3Neoplasm Metastasis 3Fallopian Tube Neoplasms 3Breast Diseases 3Uterine Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Hereditary Sensory and Autonomic Neuropathies 2Head and Neck Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Urologic Neoplasms 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Sex Cord-Gonadal Stromal Tumors 1Sarcoma, Endometrial Stromal 1Sarcoma 1Recurrent Uterine Corpus Carcinoma 1Recurrence 1Pancreatic Neoplasms 1Liposarcoma 1Genital Neoplasms, Female 1

Interventions

pembrolizumab 6Nivolumab 3Cisplatin 3Carboplatin 3Paclitaxel 2Fluorouracil 2tucatinib 1pertuzumab 1milademetan 1lenvatinib 1cemiplimab 1Trastuzumab 1Tomography, X-Ray Computed 1Ritonavir 1Radiation 1Prednisone 1Prednisolone 1Positron-Emission Tomography 1Pemetrexed 1Oxaliplatin 1Magnetic Resonance Imaging 1Leucovorin 1Itraconazole 1Gemcitabine 1Fulvestrant 1Cetuximab 1Capecitabine 1Brachytherapy 1Bevacizumab 1AZD9833 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Biliary Tract Neoplasms × Fulvestrant × Gynecologic × Clear all
NCT04579380 2025-12-19

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Seagen Inc.

Phase 2 Active not recruiting
217 enrolled 19 charts
BreastGastrointestinalGenitourinaryGynecologicThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Urologic Neoplasms, Uterine Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡